PTC Therapeutics, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:PTCT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Total assets 2.66 B2.63 B2.64 B2.9 B2.87 B3.25 B Total liabilities 2.84 B2.84 B2.8 B3.1 B3.05 B3.42 B Total equity -185.76 M-206.55 M-155.76 M-205.31 M-180.47 M-165.36 M Total liabilities & shareholders' equities 2.66 B2.63 B2.64 B2.9 B2.87 B3.25 B Total debt 285.71 M286.01 M574.41 M575.04 M—596.97 M Net debt 285.71 M286.01 M-1.4 B-1.66 B—-1.63 B

News

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential (NASDAQ:PTCT)

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Top 3 Health Care Stocks You'll Regret Missing This Quarter - PTC Therapeutics (NASDAQ:PTCT), Legend Biot

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN)

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know